1. Home
  2. NNBR vs LUNG Comparison

NNBR vs LUNG Comparison

Compare NNBR & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NN Inc.

NNBR

NN Inc.

HOLD

Current Price

$1.24

Market Cap

81.8M

Sector

Industrials

ML Signal

HOLD

Logo Pulmonx Corporation

LUNG

Pulmonx Corporation

HOLD

Current Price

$1.61

Market Cap

72.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNBR
LUNG
Founded
1980
1995
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Industrial Specialties
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
81.8M
72.2M
IPO Year
1996
2020

Fundamental Metrics

Financial Performance
Metric
NNBR
LUNG
Price
$1.24
$1.61
Analyst Decision
Strong Buy
Buy
Analyst Count
1
7
Target Price
$3.00
$5.38
AVG Volume (30 Days)
212.4K
639.0K
Earning Date
06-12-2026
06-01-2026
Dividend Yield
N/A
N/A
EPS Growth
3.60
7.64
EPS
N/A
N/A
Revenue
$770,657,000.00
$90,497,000.00
Revenue This Year
$8.27
$6.20
Revenue Next Year
$5.38
$21.61
P/E Ratio
N/A
N/A
Revenue Growth
N/A
8.01
52 Week Low
$1.10
$1.31
52 Week High
$2.67
$8.10

Technical Indicators

Market Signals
Indicator
NNBR
LUNG
Relative Strength Index (RSI) 30.95 47.75
Support Level $1.20 $1.44
Resistance Level $1.43 $1.69
Average True Range (ATR) 0.09 0.17
MACD -0.03 0.01
Stochastic Oscillator 6.17 27.33

Price Performance

Historical Comparison
NNBR
LUNG

About NNBR NN Inc.

NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: